ANNEXON, INC. Comprehensive Income
ANNEXON, INC. (ANNX) reported Comprehensive Income of -$55.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12
- ANNEXON, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$55.35M.
- ANNEXON, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$44.19M.
- ANNEXON, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$48.21M.
- ANNEXON, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$54.91M.
- ANNEXON, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$206.73M.
- ANNEXON, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$138.14M.
- ANNEXON, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$133.92M.
- ANNEXON, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$142.14M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$55.35M 10-Q · filed 2026-08-12 | -$99.54M 10-Q · filed 2026-08-12 | -$147.75M derived: sum of 3 quarters · filed 2026-08-12 | -$202.66M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$44.19M 10-Q · filed 2026-05-07 | -$92.40M derived: sum of 2 quarters · filed 2026-05-07 | -$147.31M derived: sum of 3 quarters · filed 2026-05-07 | -$196.47M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$48.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$103.11M derived: sum of 2 quarters · filed 2026-03-30 | -$152.27M derived: sum of 3 quarters · filed 2026-08-12 | -$206.73M 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$54.91M 10-Q · filed 2025-11-10 | -$104.06M derived: sum of 2 quarters · filed 2026-08-12 | -$158.52M 10-Q · filed 2025-11-10 | -$207.18M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$49.16M 10-Q · filed 2026-08-12 | -$103.61M 10-Q · filed 2026-08-12 | -$152.27M derived: sum of 3 quarters · filed 2026-08-12 | -$186.93M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$54.46M 10-Q · filed 2026-05-07 | -$103.11M derived: sum of 2 quarters · filed 2026-05-07 | -$137.77M derived: sum of 3 quarters · filed 2026-05-07 | -$167.37M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$48.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$83.31M derived: sum of 2 quarters · filed 2026-03-30 | -$112.91M derived: sum of 3 quarters · filed 2026-03-30 | -$138.14M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$34.66M 10-Q · filed 2025-11-10 | -$64.25M derived: sum of 2 quarters · filed 2025-11-10 | -$89.48M 10-Q · filed 2025-11-10 | -$117.30M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$29.60M 10-Q · filed 2025-08-14 | -$54.82M 10-Q · filed 2025-08-14 | -$82.64M derived: sum of 3 quarters · filed 2025-08-14 | -$115.08M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$25.23M 10-Q · filed 2025-05-12 | -$53.05M derived: sum of 2 quarters · filed 2025-05-12 | -$85.48M derived: sum of 3 quarters · filed 2025-05-12 | -$120.62M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$27.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$60.25M derived: sum of 2 quarters · filed 2025-03-03 | -$95.40M derived: sum of 3 quarters · filed 2025-03-03 | -$133.92M 10-K · filed 2025-03-03 | |
| 2023-09-30 | -$32.43M 10-Q · filed 2024-11-14 | -$67.58M derived: sum of 2 quarters · filed 2024-11-14 | -$106.10M 10-Q · filed 2024-11-14 | -$140.45M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$35.14M 10-Q · filed 2024-08-12 | -$73.66M 10-Q · filed 2024-08-12 | -$108.01M derived: sum of 3 quarters · filed 2024-08-12 | -$143.03M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$38.52M 10-Q · filed 2024-05-13 | -$72.87M derived: sum of 2 quarters · filed 2024-05-13 | -$107.89M derived: sum of 3 quarters · filed 2024-05-13 | -$145.09M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$34.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$69.37M derived: sum of 2 quarters · filed 2024-03-26 | -$106.57M derived: sum of 3 quarters · filed 2024-03-26 | -$142.14M 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$35.02M 10-Q · filed 2023-11-13 | -$72.22M derived: sum of 2 quarters · filed 2023-11-13 | -$107.79M 10-Q · filed 2023-11-13 | -$145.27M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$37.20M 10-Q · filed 2023-08-07 | -$72.77M 10-Q · filed 2023-08-07 | -$110.25M derived: sum of 3 quarters · filed 2023-08-07 | -$145.85M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$35.57M 10-Q · filed 2023-05-08 | -$73.04M derived: sum of 2 quarters · filed 2023-05-08 | -$108.65M derived: sum of 3 quarters · filed 2023-05-08 | -$139.91M derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | -$37.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$73.08M derived: sum of 2 quarters · filed 2023-03-06 | -$104.34M derived: sum of 3 quarters · filed 2023-03-06 | -$130.43M 10-K · filed 2023-03-06 | |
| 2021-09-30 | -$35.61M 10-Q · filed 2022-11-03 | -$66.86M derived: sum of 2 quarters · filed 2022-11-03 | -$92.95M 10-Q · filed 2022-11-03 | -$116.14M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$31.26M 10-Q · filed 2022-08-08 | -$31.28M 10-Q · filed 2021-08-16 | -$57.34M 10-Q · filed 2022-08-08 | -$80.53M derived: sum of 3 quarters · filed 2022-08-08 | -$96.17M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$26.09M 10-Q · filed 2022-05-09 | -$26.03M 10-Q · filed 2021-05-17 | -$49.28M derived: sum of 2 quarters · filed 2022-05-09 | -$64.91M derived: sum of 3 quarters · filed 2022-05-09 | -$77.14M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$23.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$38.83M derived: sum of 2 quarters · filed 2022-03-01 | -$51.06M derived: sum of 3 quarters · filed 2022-03-01 | -$63.41M 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$15.63M 10-Q · filed 2021-11-09 | -$27.86M derived: sum of 2 quarters · filed 2021-11-09 | -$40.22M 10-Q · filed 2021-11-09 | -$49.16M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$12.23M 10-Q · filed 2021-08-16 | -$24.58M 10-Q · filed 2021-08-16 | -$33.52M derived: sum of 3 quarters · filed 2021-08-16 | -$43.72M derived: sum of 4 quarters · filed 2021-08-16 | |
| 2020-03-31 | -$12.35M 10-Q · filed 2021-05-17 | -$21.29M derived: sum of 2 quarters · filed 2021-05-17 | -$31.49M derived: sum of 3 quarters · filed 2021-05-17 | -$40.89M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | -$8.94M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$19.13M derived: sum of 2 quarters · filed 2021-03-25 | -$28.54M derived: sum of 3 quarters · filed 2021-03-25 | -$37.20M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$10.20M 10-Q · filed 2020-11-16 | -$19.60M derived: sum of 2 quarters · filed 2020-11-16 | -$28.26M 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | -$9.40M 10-Q · filed 2020-09-08 | -$18.06M 10-Q · filed 2020-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |